Successful treatment of pityriasis rubra pilaris (type 1) under combination of infliximab and methotrexate.
Pityriasis rubra pilaris (PRP) is often difficult to treat. A 65-year-old women presented with a two week history of widespread erythroderma and scaling with areas of sparing (nappes claires). She also had follicular hyperkeratoses and palmar fissuring. The clinical picture and histology led to the diagnosis of PRP. She failed to respond to initial therapy which included topical and systemic corticosteroids. She was then treated with intravenous methotrexate (MTX) 15-30 mg weekly. Because of the poor response we intensified her regime with infliximab (5 mg/kg). Altogether our patient received infliximab three times together with MTX, which was later given orally. We report for the first time the successful combination of infliximab and MTX for the treatment of PRP.
Barth
Dietrich
D
Department of Dermatology, Venereology and Allergy, University of Leipzig, Philipp-Rosenthal-Strasse 23, Germany. dietrich.barth@medizin.uni-leipzig.de
Harth
Wolfgang
W
Treudler
Regina
R
Simon
Jan C
JC
D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D003879:Dermatologic Agents / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D000069285:Infliximab; D008727:Methotrexate / Q000008:administration & dosage*; D010916:Pityriasis Rubra Pilaris / Q000188:drug therapy* / Q000473:pathology*; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D000964:Antimetabolites, Antineoplastic; D003879:Dermatologic Agents; D000069285:Infliximab; D008727:Methotrexate